National Taiwan University Hospital: Carcinoma, Transitional Cell trials

The registry lists 11 Carcinoma, Transitional Cell studies with National Taiwan University Hospital as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 2 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based TherapyNot yet recruitingNCT07072637
• Urine Omics Predicting IO Therapy Responses in mUC PatientsRecruitingNCT04641936
• BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial CarcinomaStatus unknownNCT02278978Phase 2
• EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma CellsStatus unknownNCT01993966
• The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial CarcinomaStatus unknownNCT01968928
• Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in TaiwanStatus unknownNCT00867633
• Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial CarcinomaStatus unknownNCT00867620
• Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial CarcinomaStatus unknownNCT00854464
• Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCCCompletedNCT00173862Phase 2
• Chemoprevention Trial for Uremia-Associated Urothelial CarcinomaWithdrawnNCT00172367Phase 2
• Weekly TP-HDFL in the Treatment of Advanced TCCCompletedNCT00154687Phase 2